Pamiparib is an Orally Active PARP Inhibitor for Various Cancers Research
Pancreatic cancer is an extremely lethal disease with a poor prognosis. Traditional chemotherapeutic agent could improve the prognosis of the pancreatic cancer. For example, poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi)…